Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accumulated Expenses (2016 - 2018)

Viking Therapeutics' Accumulated Expenses history spans 5 years, with the latest figure at $34000.0 for Q1 2018.

  • For Q1 2018, Accumulated Expenses changed N/A year-over-year to $34000.0; the TTM value through Mar 2018 reached $34000.0, changed N/A, while the annual FY2017 figure was $22000.0, 36.95% down from the prior year.
  • Accumulated Expenses for Q1 2018 was $34000.0 at Viking Therapeutics, up from $22000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $183611.0 in Q4 2015 and bottomed at $9982.0 in Q3 2017.
  • The 5-year median for Accumulated Expenses is $47113.5 (2016), against an average of $70009.8.
  • The largest annual shift saw Accumulated Expenses plummeted 91.37% in 2016 before it surged 467.51% in 2017.
  • A 5-year view of Accumulated Expenses shows it stood at $77222.0 in 2014, then skyrocketed by 137.77% to $183611.0 in 2015, then crashed by 81.0% to $34894.0 in 2016, then tumbled by 36.95% to $22000.0 in 2017, then skyrocketed by 54.55% to $34000.0 in 2018.
  • Per Business Quant, the three most recent readings for VKTX's Accumulated Expenses are $34000.0 (Q1 2018), $22000.0 (Q4 2017), and $9982.0 (Q3 2017).